Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Rhea-AI Summary
Daré Bioscience (NASDAQ: DARE) announced that President and CEO Sabrina Martucci Johnson participated in the Virtual Investor “Why Now” on-demand series, where she presented the company’s investment thesis. The webcast highlights Daré’s mission to advance innovative, science-based and capital-efficient solutions addressing significant unmet needs in women’s health.
According to Daré Bioscience, Ms. Johnson emphasized the company’s first direct product launch, its diversified development pipeline, and its collaboration-driven strategy. The video webcast is available for on-demand viewing, and additional information about Daré’s focus areas across contraception, menopause, sexual and vaginal health, fertility, and infectious disease is available on the company’s website.
Positive
- None.
Negative
- None.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 26 | Phase 1 data publication | Positive | -8.5% | Published sildenafil cream tolerability and localized exposure findings in postmenopausal women |
| Aug 25 | CEO investor presentation | Positive | +2.4% | CEO discussed commercialization, pipeline progress, and potential catalysts during investor presentation |
| Aug 18 | Leadership recognition | Positive | -5.8% | CEO received Forbes recognition amid transition toward a multi-product women’s health company |
| Aug 14 | Registered direct offering | Negative | -34.3% | Company priced a $6.0 million registered direct offering with concurrent warrants |
| Aug 13 | Second-quarter earnings | Positive | -34.3% | Revenue increased and net loss narrowed as commercialization initiatives advanced |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
DARE historically diverged negatively from favorable or informational announcements, while the recent financing announcement aligned with a substantial decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Video webcast now available here
SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor “Why Now” on-demand series.
For the webcast, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlighting its mission to advance innovative solutions that address significant unmet needs in women's health through a differentiated, science based and capital-efficient business model. Ms. Johnson underscored Daré Bioscience's first direct product launch, its diversified pipeline, and its strategic collaboration-driven development approach.
The video webcast is now accessible for on-demand viewing here.
ABOUT DARÉ BIOSCIENCE, INC.
Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.
Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
